Big Pharma is not happy about this

US Market Approval - No Side Effects or Addiction Risk

A You are receiving this email because you subscribed to SMH News. If you wish to unsubscribe, click here.  By now, you have heard the news rumblings. After 10 years of testing, Conolidine "Nature's Morphine" is APPROVED to come to the US market effective immediately.   As you now know, Conolidine is the most powerful natural pain reliever in the world, boasting pharmaceutical level relief with no negative effects.  Remember this Harvard headline? This is just one of MANY now online. >>> Go here to learn how Conolidine eases daily pain without side effects or addiction risk Imagine a relief compound 20X the power of CBD.   Imagine lowering your pain levels by 80% or 90% without any drugs or life changes. …. And at 1/10th the cost of dangerous "pain management" As of today you can access all of this without a script or even a doctor's visit.  >>> All you have to do is visit this page to access the first Conoldine formula publicly available If you hurt daily you could be minutes away from a lifetime of relief.  To confirm, Conolidine is certified drug-free and legal to use in the US and all over the world. You can even travel with it. >>> All you have to do is visit this exclusive page dedicated to Conolidine Clint Winters, Medical Scientist P.S. One last bit of info, this powerful ingredient has gone through five years of clinical testing showing a 92% relief success rate.  >>> You can view the stunning results here P.P.S. Final thought - Big Pharma is not happy about this newly public information, they could try to censor this page at any time.     Our goal at SMH News is to bring you special opportunities we believe you, as a valued reader, will enjoy. Above is one of them from our colleagues. SMH News  |  Jun 20, 2023  © 2023 SMH News. All Rights Reserved. 6526 Old Brick Road Suite 120-121 Windermere, FL 34786   If for any reason you believe you received this email in error, you can safely ignore it, or click here to unsubscribe.